NAME: IDE196-009
What kind of cancer is this for? Uveal melanoma
Phase: II
Who is this trial for? Men and women with primary uveal melanoma that requires either removal of the eye or radiation therapy.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05907954
Brief summary of trial: This study is looking to see how people feel while they are taking the study drug, as well as how safe it is.
Need to know: The study drug is a pill, and you will have many eye exams during the trial.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
NAME: IDE196-002
What kind of cancer is this for? Metastatic Uveal melanoma
Phase: II/III
Who is this trial for? Men and women with uveal melanoma that has spread to other parts of their body.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05987332
Brief summary of trial: This study is looking at how well the study drug (IDE196) plus crizotinib works, as well as how you feel when taking it.
Need to know: Your serotype must be HLA-A*02:01 negative.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email [email protected]
Name of Trial: V940 (Merck)
What type of cancer is this for? Melanoma
Phase of this trial: Phase 3
Who is this trial for? Men and Women with high-risk stage II-IV melanoma.
What biomarkers are involved? none
What is National Clinical Trial #? NCT05933577
Brief summary of trial: A Phase 3 blinded clinical trial looking at a combination of Immunotherapy (pembrolizumab) plus V940 vaccine/placebo, in patients with surgically resected melanoma.
Need to know information: Individuals who have had surgical resection of Stage II-IV melanoma of the skin, who have not had any previous treatment beyond surgery.
Where is this trial available? The Cancer and Hematology Centers at Lemmon-Holton and other sites nationwide, click on link above to review.
For more information, please call 616-975-3065 or email [email protected]